The core aim of this project is to elucidate the nature, molecular foundations, underlying neurochemistry, and clinical correlates of neural systems-level dysfunction in schizophrenia. Toward that end, this year, the Clinical and Translational Neuroscience Branch has successfully executed comprehensive, multimodal positron emission tomography- and magnetic resonance imaging-based studies of a unique and steadily growing cohort of individuals with schizophrenia who have agreed to be studied under placebo (medication-free) conditions in comparison to matched healthy individuals. Though this work is necessarily challenging to conduct, we continue to make progress in data collection, which includes characterization of dopamine-dependent mnemonic and reward-related neural responses, striatal presynaptic dopamine synthetic capacity, and both D1 and D2/3 receptor availability, as well as prefrontal measurements of GABA and glutamate concentrations. In order to develop precision, personalized clinical care in the treatment of schizophrenia, greater neurobiological understanding is needed of the high variability across individuals in medication response. Over the past year, in efforts to address this knowledge gap, we have focused our work on identifying not only important alterations in neural systems that accompany schizophrenia in the absence of medication, but also the neurochemical predictors of neuroleptic-driven changes in brain activity and symptom burden. For example, in work focused on subcortical neural systems in schizophrenia, we have employed positron emission tomography methods to understand the functional and neurochemical consequences of antipsychotic treatment. In the dopamine receptor-rich striatum, where some individuals with schizophrenia or genetic risk factors for schizophrenia demonstrate increased dopamine synthesis capacity, resting neural activity in patients may change with neuroleptic treatment; however, whether this may be relevant to medication response and whether dopamine system characteristics underlie variance in medication-induced striatal activity changes is not established. Therefore, we studied inpatients who underwent several weeks of blinded medication withdrawal to determine PET-measured striatal regional cerebral blood flow (rCBF) and presynaptic dopamine synthesis capacity. Striatal rCBF was markedly higher during antipsychotic therapy relative to placebo. Integrating these findings in the brain with our recent work on constructing an approach to psychopathology measurement using the Positive and Negative Syndrome Scale (PANSS), we found that medication-related increases in ventral striatal rCBF were associated with more robust amelioration of excitement symptoms during active medication. Furthermore, in the ventral striatum, rCBF increases were also predicted by greater dopamine synthesis capacity during placebo treatment. These data indicate that atypical medications enact measurable physiological alterations in limbic striatal circuitry, that these alterations vary as a function of dopaminergic tone, and that they may be relevant to aspects of therapeutic response. In longitudinal studies utilizing MRS to assay GABA concentrations in the frontal cortex in patients with schizophrenia undergoing blinded medication-free periods, we found no GABA level differences when antipsychotic and placebo treatment conditions were compared. Though not establishing MRS-derived GABA levels as a robust biomarker in regard to treatment response, this negative finding serves as an important point of reference for the schizophrenia spectroscopy literature and for further neurochemical study. Finally, analyses are underway for two completed personalized-medicine drug trials examining interactions between genotype for COMT, an enzyme important for maintaining cortical dopamine, and effects of dopamine-modulating medication on cognitive function in schizophrenia. Results from these integrative, multimodal, pharmacogenetic clinical data will inform models of dopamine-linked cognitive dysfunction and remediation. This work involves the following studies: NCT00942981, NCT00001258, NCT00024622, NCT00004571, NCT00001247,NCT00001486, NCT00044083, NCT00057707

Project Start
Project End
Budget Start
Budget End
Support Year
25
Fiscal Year
2017
Total Cost
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
Zip Code
Loeb, Frances F; Zhou, Xueping; Craddock, Kirsten E S et al. (2018) Reduced Functional Brain Activation and Connectivity During a Working Memory Task in Childhood-Onset Schizophrenia. J Am Acad Child Adolesc Psychiatry 57:166-174
Reed, Jessica L; D'Ambrosio, Enrico; Marenco, Stefano et al. (2018) Interaction of childhood urbanicity and variation in dopamine genes alters adult prefrontal function as measured by functional magnetic resonance imaging (fMRI). PLoS One 13:e0195189
Ursini, Gianluca; Punzi, Giovanna; Chen, Qiang et al. (2018) Convergence of placenta biology and genetic risk for schizophrenia. Nat Med 24:792-801
Dickinson, Dwight (2017) ""If the Shoe Fits …"": The Hierarchical Structure of Psychopathology and Psychiatric Neuroimaging. Biol Psychiatry Cogn Neurosci Neuroimaging 2:303-304
Craddock, Kirsten E S; Zhou, Xueping; Liu, Siyuan et al. (2017) Symptom dimensions and subgroups in childhood-onset schizophrenia. Schizophr Res :
Dickinson, Dwight; Pratt, Danielle N; Giangrande, Evan J et al. (2017) Attacking Heterogeneity in Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data. Schizophr Bull :
Jabbi, Mbemba; Cropp, Brett; Nash, Tiffany et al. (2017) BDNF Val66Met polymorphism tunes frontolimbic circuitry during affective contextual learning. Neuroimage 162:373-383
Eisenberg, Daniel Paul; Yankowitz, Lisa; Ianni, Angela M et al. (2017) Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions. Neuropsychopharmacology 42:2232-2241
Marenco, Stefano; Meyer, Christian; Kuo, Susan et al. (2016) Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings. Am J Psychiatry 173:527-34
Masdeu, Joseph C; Dalmau, Josep; Berman, Karen F (2016) NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis? Trends Neurosci 39:300-310

Showing the most recent 10 out of 24 publications